Juergen C. Becker

1.9k total citations
18 papers, 1.4k citations indexed

About

Juergen C. Becker is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Juergen C. Becker has authored 18 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 7 papers in Molecular Biology and 6 papers in Immunology. Recurrent topics in Juergen C. Becker's work include Polyomavirus and related diseases (7 papers), Melanoma and MAPK Pathways (4 papers) and Immunotherapy and Immune Responses (4 papers). Juergen C. Becker is often cited by papers focused on Polyomavirus and related diseases (7 papers), Melanoma and MAPK Pathways (4 papers) and Immunotherapy and Immune Responses (4 papers). Juergen C. Becker collaborates with scholars based in Germany, United States and Austria. Juergen C. Becker's co-authors include David Schrama, Roland Houben, Marion Wobser, Paul Nghiem, Margaret M. Madeleine, Jayasri G. Iyer, Denise A. Galloway, Kelly G. Paulson, Petra Keikavoussi and Mads Hald Andersen and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Juergen C. Becker

18 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Juergen C. Becker Germany 15 941 542 412 381 336 18 1.4k
Christian Adam Germany 16 475 0.5× 397 0.7× 346 0.8× 202 0.5× 168 0.5× 23 1.1k
Felix Kiecker Germany 19 837 0.9× 324 0.6× 405 1.0× 282 0.7× 230 0.7× 48 1.4k
Cathrin Ritter Germany 14 647 0.7× 258 0.5× 199 0.5× 256 0.7× 207 0.6× 23 840
Margot Brickelmaier United States 13 464 0.5× 376 0.7× 339 0.8× 188 0.5× 66 0.2× 15 1.1k
Kelly L. Harms United States 15 1.3k 1.4× 48 0.1× 323 0.8× 803 2.1× 682 2.0× 22 1.5k
Subhashini Sadasivam India 8 555 0.6× 96 0.2× 858 2.1× 128 0.3× 107 0.3× 12 1.2k
Luciane T. Kagohara United States 15 576 0.6× 253 0.5× 504 1.2× 105 0.3× 91 0.3× 41 1.2k
Ayuko Taniguchi Japan 14 359 0.4× 102 0.2× 299 0.7× 88 0.2× 63 0.2× 25 725
Ping An United States 10 323 0.3× 88 0.2× 361 0.9× 137 0.4× 84 0.3× 12 754
Ling Ling Chen United States 10 388 0.4× 178 0.3× 369 0.9× 140 0.4× 51 0.2× 18 891

Countries citing papers authored by Juergen C. Becker

Since Specialization
Citations

This map shows the geographic impact of Juergen C. Becker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Juergen C. Becker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Juergen C. Becker more than expected).

Fields of papers citing papers by Juergen C. Becker

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Juergen C. Becker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Juergen C. Becker. The network helps show where Juergen C. Becker may publish in the future.

Co-authorship network of co-authors of Juergen C. Becker

This figure shows the co-authorship network connecting the top 25 collaborators of Juergen C. Becker. A scholar is included among the top collaborators of Juergen C. Becker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Juergen C. Becker. Juergen C. Becker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Ferdinandus, Justin, Wolfgang P. Fendler, Katharina Lueckerath, et al.. (2021). Response to Combined Peptide Receptor Radionuclide Therapy and Checkpoint Immunotherapy with Ipilimumab Plus Nivolumab in Metastatic Merkel Cell Carcinoma. Journal of Nuclear Medicine. 63(3). 396–398. 26 indexed citations
2.
3.
Hafner, Christian, Roland Houben, Cathrin Ritter, et al.. (2012). Activation of the PI3K/AKT Pathway in Merkel Cell Carcinoma. PLoS ONE. 7(2). e31255–e31255. 64 indexed citations
4.
Paulson, Kelly G., Jayasri G. Iyer, Andrew Tegeder, et al.. (2011). Transcriptome-Wide Studies of Merkel Cell Carcinoma and Validation of Intratumoral CD8+ Lymphocyte Invasion As an Independent Predictor of Survival. Journal of Clinical Oncology. 29(12). 1539–1546. 224 indexed citations
5.
Patel, Poulam M., Stefan Suciu, Laurent Mortier, et al.. (2011). Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: Final results of a randomised phase III study (EORTC 18032). European Journal of Cancer. 47(10). 1476–1483. 142 indexed citations
6.
Paulson, Kelly G., Joseph J. Carter, Lisa Johnson, et al.. (2010). Antibodies to Merkel Cell Polyomavirus T Antigen Oncoproteins Reflect Tumor Burden in Merkel Cell Carcinoma Patients. Cancer Research. 70(21). 8388–8397. 157 indexed citations
7.
Dummer, Reinhard, Sean Whittaker, Baktiar Hasan, et al.. (2010). EORTC 21012: Phase II Multicentre Study of Caelyx™ Monotherapy In Patients with Advanced Mycosis Fungoides Stage IIb, Iva and IVb with or without Previous Chemotherapy.. Blood. 116(21). 2823–2823. 4 indexed citations
8.
Vetter‐Kauczok, Claudia S., Eugene Lukanidin, Per thor Straten, et al.. (2009). Immunogenicity of HLA-A1-restricted peptides derived from S100A4 (metastasin 1) in melanoma patients. Cancer Immunology Immunotherapy. 58(8). 1265–1273. 2 indexed citations
9.
Houben, Roland, et al.. (2009). MAPK-independent impairment of T-cell responses by the multikinase inhibitor sorafenib. Molecular Cancer Therapeutics. 8(2). 433–440. 35 indexed citations
10.
Krejsgaard, Thorbjørn, Claudia S. Vetter‐Kauczok, Anders Woetmann, et al.. (2009). Ectopic expression of B-lymphoid kinase in cutaneous T-cell lymphoma. Blood. 113(23). 5896–5904. 49 indexed citations
11.
Dummer, Reinhard, Axel Hauschild, Juergen C. Becker, et al.. (2008). An Exploratory Study of Systemic Administration of the Toll-like Receptor-7 Agonist 852A in Patients with Refractory Metastatic Melanoma. Clinical Cancer Research. 14(3). 856–864. 95 indexed citations
12.
Houben, Roland, David Schrama, Marco J. Herold, et al.. (2007). Activation of the MAP Kinase Pathway Induces Apoptosis in the Merkel Cell Carcinoma Cell Line UISO. Journal of Investigative Dermatology. 127(9). 2116–2122. 21 indexed citations
13.
Houben, Roland, et al.. (2007). RKIP does not contribute to MAP kinase pathway silencing in the Merkel Cell Carcinoma cell line UISO. Journal of Carcinogenesis. 6(1). 16–16. 9 indexed citations
14.
Houben, Roland, Barbara Michel, Claudia S. Vetter‐Kauczok, et al.. (2006). Absence of Classical MAP Kinase Pathway Signalling in Merkel Cell Carcinoma. Journal of Investigative Dermatology. 126(5). 1135–1142. 46 indexed citations
15.
Wobser, Marion, et al.. (2006). Expression pattern of the lymphatic and vascular markers VEGFR-3 and CD31 does not predict regional lymph node metastasis in cutaneous melanoma. Archives of Dermatological Research. 297(8). 352–357. 18 indexed citations
16.
Wobser, Marion, Heike Voigt, Roland Houben, et al.. (2006). Dendritic cell based antitumor vaccination: impact of functional indoleamine 2,3-dioxygenase expression. Cancer Immunology Immunotherapy. 56(7). 1017–1024. 62 indexed citations
17.
Wobser, Marion, et al.. (2005). Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin. Cancer Immunology Immunotherapy. 55(10). 1294–1298. 127 indexed citations
18.
Xiang, Rong, Noriko Mizutani, Yunping Luo, et al.. (2005). A DNA Vaccine Targeting Survivin Combines Apoptosis with Suppression of Angiogenesis in Lung Tumor Eradication. Cancer Research. 65(2). 553–561. 132 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Christian Adam Breakdown of academic impact, for papers by Felix Kiecker Breakdown of academic impact, for papers by Cathrin Ritter Breakdown of academic impact, for papers by Margot Brickelmaier Breakdown of academic impact, for papers by Kelly L. Harms Breakdown of academic impact, for papers by Subhashini Sadasivam Breakdown of academic impact, for papers by Luciane T. Kagohara Breakdown of academic impact, for papers by Ayuko Taniguchi Breakdown of academic impact, for papers by Ping An Breakdown of academic impact, for papers by Ling Ling Chen
Rankless by CCL
2026